Medical Devices

Cordis announces clinical and educational programs for CYPHER Sirolimus-eluting Coronary Stent

Published in Medical Letter on the CDC and FDA, January 7th, 2007

Cordis Corporation stated to an advisory panel to the U.S. Food and Drug Administration (FDA) that analysis of its research on the CYPHER Sirolimus-eluting Coronary Stent suggests a need for additional education on anti-platelet therapy regimens for bare-metal and drug-eluting stent patients and further research to understand safety factors.

Further, Cordis committed to support efforts by the clinical community, medical societies and industry to achieve these goals. The company's conclusions are based on an independent analysis of long-term clinical data for the CYPHER Stent that were presented recently.

This independent analysis, conducted and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2007-01-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry